Association for Accessible Medicines

We’re thrilled to announce Alex Azar, former Secretary of the U.S. Department of Health and Human Services, a featured keynote speaker for #Access2025.    A visionary leader in healthcare, Secretary Azar spearheaded initiatives like Operation Warp Speed and key reforms. With unparalleled experience in government and the private sector, Azar will share insights to inspire, inform, and challenge us to reimagine our industry's future.    Don’t miss this opportunity to hear from one of healthcare’s most impactful leaders. Register today: https://lnkd.in/dg4cPyZJ

AAM Applauds Senate Bill to Protect Patient Access to Affordable Medicines: “This legislation is imperative for U.S. patients,” said John Murphy III, President & CEO for AAM. “When generic medicines become available, they bring immediately lower prices for lifesaving and lifechanging medications. We are thankful for the work done thus far by Senators Welch, Cotton, Collins, and Hickenlooper; and our association greatly appreciates the efforts of the Senate to expedite access to generic and biosimilar medicines by protecting skinny labeling.” MORE: https://lnkd.in/erU7dEs5

AAM is encouraging legislators to pass critically important healthcare provisions within the Congressional continuing resolution: “The healthcare provisions in the year-end funding bill are a double win—streamlining patient access to affordable #generic and #biosimilar medicines and saving the government money,” said John Murphy III, President and CEO of AAM. “AAM applauds Congress for including these measures in the CR, and strongly encourages passage. Among many positive reforms included in the package, this bill will help patients by bringing down costs of medication by streamlining FDA processes, prohibiting patent manipulation in the biosimilars market, arresting the arcane pricing practices of pharmacy benefit managers, and ensuring the hard-working members of the government healthcare system remain on point to look out for the interests of the American patient. These provisions will not only bring lower-cost medicines to patients sooner, but they will also increase efficiencies in government programs and approvals and reduce federal healthcare spending for the long term. Thank you to Congressional leaders and committee chairs for working hard on behalf of all American patients.” #Congress #healthcare Biosimilars Council

Brand drug manufacturers often enjoy years of exclusivity, leading to repeated price hikes for patients. Generic and biosimilar medicines can lower costs and improve access, but savings are hindered by patent thickets and PBM rebate practices. These barriers delay health plan coverage for new generics and biosimilars, impacting patient care. Learn more in #GRxBiosimsSavingsReport: https://lnkd.in/e9xGNTfW

DRUG SHORTAGES HAMPER PATIENT CARE! The increase in #generic shortages is a result of unsustainably low pricing, increases in government policies that further compound market dynamics, and regulatory challenges. Learn more in the 2024 #GRxBiosimsSavingsReport: https://lnkd.in/e9xGNTfW

As Congress debates a final package of legislation to end the 2024 session there are many important policies that we are pushing to be included to accelerate patients' access to affordable generic and biosimilar medicines. A key priority includes allowing FDA to collaborate with manufacturers to ensure faster transparency into the underlying ingredient mix necessary to achieve safe and effective approvals of new generic medicines. This is a long-supported FDA proposal that will significantly streamline FDA review and ultimately benefit patients. #healthsecurity Association for Accessible Medicines Biosimilars Council

Join us at #Access2025, AAM’s annual meeting from Feb 3–5 in Amelia Island, FL! This event is a unique opportunity to connect with policymakers, industry leaders, and influential speakers. Engage in discussions that will shape the future of generics and biosimilars. Don’t miss out on key insights and networking opportunities. Register now! https://lnkd.in/dg4cPyZJ

Today from Lachman Consultant Services: “The Association for Accessible Medicines (AAM) recently mentioned a report titled “Study: 57 Percent of Covered Generic Drugs Not on Part D Generic Tiers in 2025” (here), conducted by Avalere, that raises serious questions regarding the Centers for Medicare and Medicaid Services (CMS) placement of many generic drugs on higher tiers… A reevaluation of the process is needed to save both patients and the government what could be billions of dollars.” READ: https://lnkd.in/eqS6VFvq

Biosimilar medicines significantly reduce costs and increase lifesaving treatment options for patients. Since 2015, #biosimilars have been used in 2.7 billion days of patient therapy and have supported 495 million incremental days of therapy that patients would otherwise not have received. More: https://lnkd.in/emdKKqjY Association for Accessible Medicines

Decisions by PBMs and health plans to shift #generics to non-generic tiers increases copays and imposes higher costs on patients. THE BOTTOM LINE: U.S. patients are overpaying for medicines because of PBMs. Learn the facts: https://lnkd.in/e9xGNTfW #GRxBiosimsSavingsReport